货号：E-T202508210001
CAS：N/A
规格：mg
纯度：≥95%
生产商：试剂家

生物活性：ML218-d9 is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
ML218-d9 相关抗体:
Annexin VI Antibody
Calbindin Antibody
Calreticulin Antibody
Cardiac Troponin I/TNNC1 Antibody
SCGN Antibody (YA1167)
RAMP1 Antibody (YA1818)
Annexin V Antibody (YA1829)
Striatin 4 Antibody (YA2088)
Fibulin 5 Antibody (YA2448)
RASGRP1 Antibody (YA2546)
Fibulin 1 Antibody (YA2831)
EFEMP1 Antibody (YA2883)
CRCP Antibody (YA3350)
Annexin VII Antibody (YA1138)
Parvalbumin Antibody (YA1249)
Annexin IV Antibody (YA1921)
SERCA2 ATPase Antibody (YA1931)
Stromal Interaction Molecule 1 Antibody (YA2092)
SERCA1 ATPase Antibody (YA2157)
TrpV5 Antibody (YA2284)
NCX1 Antibody (YA2331)
Scramblase 1 Antibody (YA2419)
CAB39 Antibody (YA2761)
CUG BP1 Antibody (YA2806)
C10orf63 Antibody (YA2894)
ITPK1 Antibody (YA3125)
ORAI3 Antibody (YA3128)
ORAI1 Antibody (YA3157)
CREB Regulated Transcription Coactivator 2 Antibody (YA3279)
分子量：378.38
Formula：C19H17D9Cl2N2O
非标记 CAS：1346233-68-8
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (529 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Xiang Z, et al. The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
 [Content Brief]